Previous 10 | Next 10 |
2024-02-14 07:06:21 ET More on IQVIA IQVIA Q3: TAS Segment Remains The Problem Child Stock leaders for 2030 in Health Tech - UBS Seeking Alpha’s Quant Rating on IQVIA Historical earnings data for IQVIA Read the full article on Seeking Alpha ...
Revenue of $3,868 million for the fourth quarter, $14,984 million for the full year GAAP Net Income of $469 million for the fourth quarter, $1,358 million for the full year Adjusted EBITDA of $966 million for the fourth quarter, $3,569 million for the full year GAAP Dilute...
Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...
2024-02-13 14:07:22 ET Summary Fortrea stock has poor fundamentals, low revenue growth, and high debt burden, making it a strong sell. Fortrea's balance sheet is showing warning signs, with a low Altman z score and poor ratios compared to the industry. The management has no cl...
2024-02-13 11:08:43 ET More on IQVIA IQVIA Q3: TAS Segment Remains The Problem Child Stock leaders for 2030 in Health Tech - UBS U.S. judge upholds FTC bid to block Iqvia’s DeepIntent buyout Seeking Alpha’s Quant Rating on IQVIA Historic...
IQVIA ™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to the Fortune® World's Most Admired Companies™ list for the seventh consecutive year. For the third year...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. ...
2024-01-24 08:54:54 ET More on Biogen, Eisai Co., Ltd., etc. Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Eisai...
2024-01-24 01:35:00 ET Summary Cedar Creek Partners is a private investment partnership that focuses primarily on micro and small cap equities. Cedar Creek Partners is managed by Eriksen Capital Management LLC, a registered investment adviser. Cedar Creek increased by 2.8% in the ...
Growth outlook is raised by 2 percentage points despite lower expectations for COVID-19 vaccines and therapeutics This increase in growth outlook is driven by more patients getting treated with better medicines, especially in immunology, endocrinology, and oncology Medicine use in Latin A...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...
Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64 R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27...
IQVIA ™ (NYSE:IQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiven...